On Demand 2025 Sunday AM General Sessions

This collection covers general sessions from Sunday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Plenary: Joint Task Force on Practice Parameters Severe Asthma Update
  • 7 for 11: Hot Topics in Pediatrics A&I – A Joint Presentation from AAP-SOAI & ACAAI
  • Introductory Course in Rhinolaryngoscopy
  • Coding & Government Relations
  • Practical Approach to Patients With Mast Cell Concerns

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Review findings from patient focus groups to identify patient preferences and values regarding asthma care.
  • Examine adverse effects from both long-term and intermittent bursts of oral corticosteroids.
  • Compare and contrast efficacy and safety data for biologics used to treat moderate and severe asthma.
  • Compare new diagnosis and treatments for food allergy.
  • Identify updates in pediatric asthma and allergy.
  • Recognize changes in diagnosis and management of pediatric skin and immune disorders.
  • Describe the major anatomical findings in the upper airway.
  • Identify normal and abnormal anatomy, disease presentations and post-op findings.
  • Appraise indications for use of the rhinoscope in the allergist’s office.
  • Utilize ICD10 Coding through cased based approach.
  • Detail current issues from payors and CMS faced by allergists.
  • Track government issues on Capitol Hill.
  • Identify the available literature behind this commonly cited trend that patients with EDS and/or POTS are more likely to have mast cell disease.
  • Discuss efficient ways to review what mast cell disease is and isn't in a patient-centered approach.
  • Assess what tests have the highest yield in the evaluation of mast cell disease. Analyze the current literature around alpha-tryptasemia and recent management changes.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Course opens: 
11/24/2025
Course expires: 
12/07/2028
Part of: 
On Demand ACAAI 2025 Annual Scientific Meeting
Rating: 
0

Flavia Hoyte, MD, FACAAI
John J. Oppenheimer, MD, FACAAI
Giselle S. Mosnaim, MD, MS, FACAAI
Angela D. Hogan, MD, FACAAI
Theresa A. Bingemann, MD, FACAAI
J. Andrew Bird, MD, FACAAI
Eric M. Schauberger, DO, PhD, FACAAI
Julie Wang, MD, FACAAI
Vivian P. Hernandez-Trujillo, MD, FACAAI
Ama Alexis, MD, FACAAI
Cem Akin, MD, PhD, FACAAI
Mariana C. Castells, MD, PhD, FACAAI
Andrew A. White, MD, FACAAI
Jonathan Lyons, MD
Gary N. Gross, MD, FACAAI
Travis A. Miller, MD, FACAAI
Matt Reiter
Jerald W. Koepke, MD, FACAAI

Available Credit

  • 7.75 AMA PRA Category 1 Credit™
  • 7.75 Attendance
  • 7.75 CBRN
Please login or create an account to take this course.